Cargando…
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549564/ https://www.ncbi.nlm.nih.gov/pubmed/26380223 http://dx.doi.org/10.3389/fonc.2015.00193 |
_version_ | 1782387326706515968 |
---|---|
author | Geier, Brian Kurmashev, Dias Kurmasheva, Raushan T. Houghton, Peter J. |
author_facet | Geier, Brian Kurmashev, Dias Kurmasheva, Raushan T. Houghton, Peter J. |
author_sort | Geier, Brian |
collection | PubMed |
description | Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and “omics” approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents. |
format | Online Article Text |
id | pubmed-4549564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45495642015-09-14 Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation Geier, Brian Kurmashev, Dias Kurmasheva, Raushan T. Houghton, Peter J. Front Oncol Oncology Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and “omics” approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents. Frontiers Media S.A. 2015-08-26 /pmc/articles/PMC4549564/ /pubmed/26380223 http://dx.doi.org/10.3389/fonc.2015.00193 Text en Copyright © 2015 Geier, Kurmashev, Kurmasheva and Houghton. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Geier, Brian Kurmashev, Dias Kurmasheva, Raushan T. Houghton, Peter J. Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation |
title | Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation |
title_full | Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation |
title_fullStr | Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation |
title_full_unstemmed | Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation |
title_short | Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation |
title_sort | preclinical childhood sarcoma models: drug efficacy biomarker identification and validation |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549564/ https://www.ncbi.nlm.nih.gov/pubmed/26380223 http://dx.doi.org/10.3389/fonc.2015.00193 |
work_keys_str_mv | AT geierbrian preclinicalchildhoodsarcomamodelsdrugefficacybiomarkeridentificationandvalidation AT kurmashevdias preclinicalchildhoodsarcomamodelsdrugefficacybiomarkeridentificationandvalidation AT kurmashevaraushant preclinicalchildhoodsarcomamodelsdrugefficacybiomarkeridentificationandvalidation AT houghtonpeterj preclinicalchildhoodsarcomamodelsdrugefficacybiomarkeridentificationandvalidation |